CEACAM8 and Hypercholesterolemia: After twelve months statin treatment, patients with hypercholesterolemia have similar expression of cell surface activation markers compared to healthy controls, both for the percentage of positive cells, as well for the MFI, for the markers CD16, CD10, CD66b, CD11b, CD35, CD62L, and HLA-DR.